NVLX has already produced impressive results from its two independent Phase II clinical trials in patients with advanced, inoperable pancreatic cancer. Two key results pulled from the data of those trials, are that the median survival rate was higher than that of the current gold standard for the disease and better than those of other competitors' treatments when clinical trial reports are examined. Furthermore, the overall side-effect profile (toxicity) was much lower with Nuvilex's treatment than those of competitors' treatments.
Market Data 
Markets 
AI
